TransMedics Group Inc TMDX
TransMedics is a Medicare billing-fraud and kickback racket whose top transplant-center customers are fleeing as cheaper alternatives arrive — Scorpion sets a $0 target.
Thesis
Scorpion Capital alleges TransMedics (TMDX) is the most extreme healthcare fraud they have encountered in 20 years of shorting — a 'Mafia-style' extortion scheme masquerading as a medical-device company. The Organ Care System (OCS), an FDA-approved warm perfusion pump for lung, heart and liver transplants, sells at $70-90K per consumable plus six-figure aircraft and procurement fees through the National OCS Program (NOP), exploiting an uncapped Medicare 'organ acquisition charge' loophole. Scorpion documents 30+ interviews with surgeons, OPO executives and ex-employees describing kickbacks to high-volume centers, off-label use, organ trafficking, billing fraud, and unreported device failures causing necrotic livers. Pre-eminent customers — Vanderbilt, MGH, UCSF, Cedars-Sinai, Duke — are eliminating or sharply curtailing usage as cheaper NRP, OrganOx and Paragonix alternatives arrive. Scorpion targets $0 and is filing an FDA Citizen Petition seeking PMA suspension of the OCS device.
SCQA
TransMedics sells the Organ Care System, an FDA-approved warm perfusion pump for lung, heart and liver transplants, paired with the National OCS Program — a fleet of private jets, procurement surgeons and device technicians billed back to Medicare via transplant centers.
Scorpion alleges the model is a Medicare billing-fraud and kickback racket: $70-90K consumables and six-figure flight fees with no clinical benefit, organ trafficking, off-label use, unreported device failures and an enraged customer base now defecting.
Short the stock; file an FDA Citizen Petition demanding suspension of the OCS PMA; mobilize transplant surgeons, OPOs and federal/state authorities (DOJ, OIG, IRS, state AGs) to investigate alleged kickbacks, billing fraud and Medicare abuse.
Target price $0. Even at an absurd 5x product-sales multiple the stock would sit in the $30s; the air-charter half is worthless and the accelerating customer exodus from Vanderbilt, MGH, UCSF and Cedars-Sinai is already collapsing 2025 revenue.
The three reasons
- 1
Allegedly a 'Mafia-style' Medicare billing-fraud and kickback racket exploiting an uncapped organ-acquisition reimbursement loophole
- 2
Pre-eminent customers (Vanderbilt, MGH, UCSF, Cedars-Sinai, Duke) are eliminating or sharply curtailing OCS usage
- 3
OCS device has no clinical benefit — used off-label as a 'surgeon lifestyle' tool, now disrupted by NRP, OrganOx and Paragonix at a fraction of the cost
Primary demands
- Short TMDX; target price $0 (100% downside)
- FDA suspension of Premarket Approval (PMA) for the Organ Care System (OCS) via a Citizen Petition
- Federal/state investigation of alleged Medicare billing fraud, kickbacks to high-volume transplant centers, off-label device use, and unreported device failures
- Transplant surgeons, hospital administrators and OPOs to submit supporting FDA comments
KPIs cited
Pattern membership
Precedents cited
- BlackBerry obsolescence trajectory (Vanderbilt surgeon analogy)
- Air Methods False Claims Act settlement and 2023 Chapter 11 (medical air transport precedent)
- Terren Peizer / Ontrak — first DOJ criminal conviction for 10b5-1 plan abuse
Composition what's on the 342 slides
Slide gallery ·
Notes
Scorpion Capital's signature 342-page long-form investigative short report, built around 30+ expert interviews (surgeons, OPO executives, ex-employees) presented as yellow-highlighted quote walls. Heavy use of profanity verbatim from sources, named villains throughout (CEO Waleed Hassanein, COO Tamer Khayal, CMO Magdy Attia, CEO's sister Amira Hassanein). Cover discloses Scorpion is short TMDX but does not disclose a numerical position size. Document explicitly previews a forthcoming FDA Citizen Petition seeking PMA suspension and a public letter to Congress — the call-to-action is regulatory, not just a financial short pitch. Layout is text-dense throughout with embedded screenshots, TMDX investor-day chart cutouts, and SEC-filing tables; minimal original data visualization. Distinctive Scorpion masthead and rhetorical voice (Mafia/Tony Soprano/Ozymandias analogies). Page references in TOC are 1-indexed against the PDF.